non-hodgkin

IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.

PNU-159682, a metabolite of anthracycline nemorubicin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

BMS-986458 is a highly selective, orally active BCL6 PROTAC degrader. It specifically targets cereblon (CRBN) and the BCL6 N-terminal BTB domain to catalyze proximity-induced BCL6 degradation. BMS-986458 is applicable for research in B-cell non-Hodgkin lymphoma.

Sobuzoxane is an orally active topoisomerase II inhibitor that causes irreversible inhibition of cell division. Sobuzoxane can be used to study non-Hodgkin lymphoma that is resistant to conventional chemotherapy or relapsed.

Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with anti-tumor activity that inhibits the integration of HIV DNA into cellular DNA in monocytes and macrophages, inducing apoptosis. Mitoguazone can be used to prevent acute leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma.

Daunorubicin (Daunomycin) citrate, a potent anti-tumor anthracycline antibiotic, acts as a topoisomerase II inhibitor. It effectively inhibits DNA and RNA synthesis, diminishes cancer cell viability, and promotes apoptosis and necrosis. This cytotoxic compound is utilized in researching a range of cancers, such as leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, and Wilms' tumor, as well as infections [1] [2] [4] [5].

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Pinatuzumab is a humanised monoclonal antibody targeting CD22, commonly used to synthesise the ADC molecule Pinatuzumab vedotin, which is employed in the study of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).

Zuberitamab (HS-20090) is a humanized IgG1 monoclonal antibody targeting CD20. The compound specifically binds to CD20 on the surface of B cells, facilitating the depletion of malignant B cells through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the direct induction of apoptosis. In experimental studies, Zuberitamab serves as a potent tool for B-cell depletion to investigate hematological malignancies such as Non-Hodgkin Lymphoma (NHL).

Loncastuximab (RB4v1.2) is a monoclonal antibody inhibitor targeting CD19 with antitumor activity. It is used in research on non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), and for synthesizing ADC molecules such as Loncastuximab tesirine.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).

Apoptosis Inducer 11 (compound 3u) promotes apoptosis via the mitochondrial pathway and elicits a G2/M block alongside a marked reduction in the S phase within non-Hodgkin lymphoma cell lines [1].

Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Iladatuzumab vedotin (DCDS-0780A) is an ADC compound targeting CD79b, conjugated with the cytotoxic drug MMAE through a cleavable dipeptide linker mc-val-cit-PABC, used in the study of non-Hodgkin lymphoma.

BVX20 is a human monoclonal antibody that binds to CD20. It can eliminate B cells by engaging the immune system. BVX20 is applicable in the study of relapsed or chemotherapy-resistant follicular B-cell non-Hodgkin lymphoma (NHL), as well as CD20-positive diffuse large B-cell non-Hodgkin lymphoma (NHL).

Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E, and MS4A1. It consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv arm targeting CD3E and MS4A1. Anafiltamig can simultaneously bridge T cells and B cells, thus activating T cells to selectively kill B-cell tumors. This compound is applicable for research on B-cell malignancies, such as non-Hodgkin lymphoma.

Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.

Anti-CD22-NMS249 is an antibody-drug conjugate (ADC) that targets CD22, comprising the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and the effective payload of DNA topoisomerase II inhibitor PNU-159682. This compound is utilized in the study of non-Hodgkin lymphoma (NHL).

HX009 is a bispecific antibody targeting PD-1 and CD47 (EC50=0.05 nM/0.24 nM). It binds and blocks PD-1 and CD47, selectively localizes to the tumor microenvironment, and reduces hematotoxicity. It can be used to study non-Hodgkin lymphoma (NHL).

RG-6333 is a bispecific agonist targeting CD19 and CD28. It specifically identifies and binds to the CD19 antigen present on the surface of malignant B cells, effectively targeting tumor cells. By engaging with CD28, RG-6333 activates T cells, overcoming activation barriers and boosting antitumor immunity. RG-6333 is applicable for research in relapsed/refractory non-Hodgkin lymphoma.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.